NCT03466151 - RESOLUTE ONYX China RCT Study | Biotech Hunter

Enrollment

550

Participants

Timeline

Start Date

April 12, 2018

Primary Completion Date

February 12, 2021

Study Completion Date

September 19, 2025

Conditions

Ischemic Heart DiseaseStenotic Coronary LesionCardiovascular DiseasesArteriosclerosisCoronary Artery Disease

Interventions

DEVICE

Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System

Treatment of subjects eligible for percutaneous transluminal coronary angioplasty (PTCA) as per study requirements

DEVICE

Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System

Treatment of subjects eligible for percutaneous transluminal coronary angioplasty (PTCA) as per study requirements

Trial Locations (2)

Fuwai Hospital, Chinese Academy of Medical Science, Beijing

Shengjing Hospital of China Medical University, Shenyang